Compare PHAR & VREX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PHAR | VREX |
|---|---|---|
| Founded | 1988 | 2016 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 580.6M |
| IPO Year | 2020 | 2016 |
| Metric | PHAR | VREX |
|---|---|---|
| Price | $16.20 | $10.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $39.00 | $16.67 |
| AVG Volume (30 Days) | 18.5K | ★ 248.4K |
| Earning Date | 03-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | ★ $811,000,000.00 |
| Revenue This Year | $10.04 | $5.35 |
| Revenue Next Year | $2.70 | $3.88 |
| P/E Ratio | $3,041.22 | ★ $215.60 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.50 | $6.76 |
| 52 Week High | $21.34 | $14.57 |
| Indicator | PHAR | VREX |
|---|---|---|
| Relative Strength Index (RSI) | 50.30 | 32.50 |
| Support Level | $14.88 | $9.81 |
| Resistance Level | $17.70 | $12.61 |
| Average True Range (ATR) | 0.70 | 0.37 |
| MACD | 0.15 | 0.01 |
| Stochastic Oscillator | 55.67 | 33.47 |
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Varex Imaging Corp Designs, manufactures, sells, and services X-ray imaging components, including X-ray tubes, detectors, ionization chambers, high-voltage connectors, software, collimators, generators, exposure control devices, and heat exchangers.. The company operates through two segments: Medical, the key revenue driver, providing X-ray imaging components and accessories for healthcare applications, and Industrial, which provides Linatron X-ray accelerators, X-ray tubes, flat panel detectors, high-voltage connectors, and coolers for non-medical use. Geographically, it generates the majority of its revenue from Europe, the Middle East, and Africa (EMEA), with the rest coming from the Americas and Asia Pacific.